TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
The emergence of drug resistance is a major obstacle in the treatment of cancer patients. Here, the authors show that TRIB2 expression increases resistance to PI3K inhibition by promoting AKT activation and the subsequent FOXO inactivation and disruption of p53 function.
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2017
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/176359cfd25c4c82970d73e492cb40ae |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|